ID   XPC_HUMAN               Reviewed;         940 AA.
AC   Q01831; B4DIP3; E9PB96; E9PH69; Q53GT7; Q96AX0;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 4.
DT   13-NOV-2019, entry version 199.
DE   RecName: Full=DNA repair protein complementing XP-C cells;
DE   AltName: Full=Xeroderma pigmentosum group C-complementing protein;
DE   AltName: Full=p125;
GN   Name=XPC; Synonyms=XPCC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 2-55, AND
RP   VARIANTS VAL-499 AND LYS-939.
RX   PubMed=8168482; DOI=10.1002/j.1460-2075.1994.tb06452.x;
RA   Masutani C., Sugasawa K., Yanagisawa J., Sonoyama T., Ui M.,
RA   Enomoto T., Takio K., Tanaka K., van der Spek P.J., Bootsma D.,
RA   Hoeijmakers J.H.J., Hanaoka F.;
RT   "Purification and cloning of a nucleotide excision repair complex
RT   involving the Xeroderma pigmentosum group C protein and a human
RT   homologue of yeast RAD23.";
RL   EMBO J. 13:1831-1843(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS VAL-499 AND LYS-939, AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=12177305; DOI=10.1093/nar/gkf469;
RA   Khan S.G., Muniz-Medina V., Shahlavi T., Baker C.C., Inui H., Ueda T.,
RA   Emmert S., Schneider T.D., Kraemer K.H.;
RT   "The human XPC DNA repair gene: arrangement, splice site information
RT   content and influence of a single nucleotide polymorphism in a splice
RT   acceptor site on alternative splicing and function.";
RL   Nucleic Acids Res. 30:3624-3631(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Fetal brain;
RX   PubMed=24722188; DOI=10.1038/ncomms4650;
RA   Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L.,
RA   Broly M., Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S.,
RA   Tasan M., Lemmens I., Kuang X., Zhao N., Malhotra D., Michaelson J.J.,
RA   Vacic V., Calderwood M.A., Roth F.P., Tavernier J., Horvath S.,
RA   Salehi-Ashtiani K., Korkin D., Sebat J., Hill D.E., Hao T., Vidal M.,
RA   Iakoucheva L.M.;
RT   "Protein interaction network of alternatively spliced isoforms from
RT   brain links genetic risk factors for autism.";
RL   Nat. Commun. 5:3650-3650(2014).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-16; PHE-48;
RP   ARG-86; GLN-314; HIS-492; VAL-499; ILE-513; GLU-632; HIS-671; MET-689;
RP   GLN-928 AND LYS-939.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 69-940 (ISOFORM 1).
RC   TISSUE=Liver;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 119-940 (ISOFORM 1).
RX   PubMed=1522891; DOI=10.1038/359070a0;
RA   Legerski R.J., Peterson C.A.;
RT   "Expression cloning of a human DNA repair gene involved in Xeroderma
RT   pigmentosum group C.";
RL   Nature 359:70-73(1992).
RN   [10]
RP   ERRATUM.
RX   PubMed=1461286; DOI=10.1038/360610b0;
RA   Legerski R.J., Peterson C.A.;
RL   Nature 360:610-610(1992).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=8692695; DOI=10.1093/nar/24.13.2551;
RA   van der Spek P.J., Eker A., Rademakers S., Visser C., Sugasawa K.,
RA   Masutani C., Hanaoka F., Bootsma D., Hoeijmakers J.H.;
RT   "XPC and human homologs of RAD23: intracellular localization and
RT   relationship to other nucleotide excision repair complexes.";
RL   Nucleic Acids Res. 24:2551-2559(1996).
RN   [12]
RP   INTERACTION WITH RAD23A.
RX   PubMed=9372924; DOI=10.1128/mcb.17.12.6924;
RA   Sugasawa K., Ng J.M., Masutani C., Maekawa T., Uchida A.,
RA   van der Spek P.J., Eker A.P., Rademakers S., Visser C.,
RA   Aboussekhra A., Wood R.D., Hanaoka F., Bootsma D., Hoeijmakers J.H.;
RT   "Two human homologs of Rad23 are functionally interchangeable in
RT   complex formation and stimulation of XPC repair activity.";
RL   Mol. Cell. Biol. 17:6924-6931(1997).
RN   [13]
RP   FUNCTION OF THE XPC COMPLEX.
RX   PubMed=9734359; DOI=10.1016/s1097-2765(00)80132-x;
RA   Sugasawa K., Ng J.M., Masutani C., Iwai S., van der Spek P.J.,
RA   Eker A.P., Hanaoka F., Bootsma D., Hoeijmakers J.H.;
RT   "Xeroderma pigmentosum group C protein complex is the initiator of
RT   global genome nucleotide excision repair.";
RL   Mol. Cell 2:223-232(1998).
RN   [14]
RP   FUNCTION, SUBUNIT, AND INTERACTION WITH CCNH; GTF2H1 AND ERCC3.
RX   PubMed=10734143; DOI=10.1074/jbc.275.13.9870;
RA   Yokoi M., Masutani C., Maekawa T., Sugasawa K., Ohkuma Y., Hanaoka F.;
RT   "The xeroderma pigmentosum group C protein complex XPC-HR23B plays an
RT   important role in the recruitment of transcription factor IIH to
RT   damaged DNA.";
RL   J. Biol. Chem. 275:9870-9875(2000).
RN   [15]
RP   FUNCTION OF THE XPC COMPLEX.
RX   PubMed=10873465; DOI=10.1006/jmbi.2000.3857;
RA   Batty D., Rapic'-Otrin V., Levine A.S., Wood R.D.;
RT   "Stable binding of human XPC complex to irradiated DNA confers strong
RT   discrimination for damaged sites.";
RL   J. Mol. Biol. 300:275-290(2000).
RN   [16]
RP   INTERACTION WITH CETN2 AND RAD23B, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF THE XPC COMPLEX.
RX   PubMed=11279143; DOI=10.1074/jbc.m100855200;
RA   Araki M., Masutani C., Takemura M., Uchida A., Sugasawa K., Kondoh J.,
RA   Ohkuma Y., Hanaoka F.;
RT   "Centrosome protein centrin 2/caltractin 1 is part of the xeroderma
RT   pigmentosum group C complex that initiates global genome nucleotide
RT   excision repair.";
RL   J. Biol. Chem. 276:18665-18672(2001).
RN   [17]
RP   FUNCTION OF THE XPC COMPLEX.
RX   PubMed=12509299; DOI=10.1016/s1568-7864(01)00008-8;
RA   Sugasawa K., Shimizu Y., Iwai S., Hanaoka F.;
RT   "A molecular mechanism for DNA damage recognition by the xeroderma
RT   pigmentosum group C protein complex.";
RL   DNA Repair 1:95-107(2002).
RN   [18]
RP   DNA-BINDING, AND INTERACTION WITH RAD23B; ERCC2 AND GTF2H1.
RX   PubMed=12509233; DOI=10.1016/s1568-7864(02)00031-9;
RA   Uchida A., Sugasawa K., Masutani C., Dohmae N., Araki M., Yokoi M.,
RA   Ohkuma Y., Hanaoka F.;
RT   "The carboxy-terminal domain of the XPC protein plays a crucial role
RT   in nucleotide excision repair through interactions with transcription
RT   factor IIH.";
RL   DNA Repair 1:449-461(2002).
RN   [19]
RP   FUNCTION OF THE XPC COMPLEX.
RX   PubMed=12547395; DOI=10.1016/s1568-7864(02)00222-7;
RA   Janicijevic A., Sugasawa K., Shimizu Y., Hanaoka F., Wijgers N.,
RA   Djurica M., Hoeijmakers J.H., Wyman C.;
RT   "DNA bending by the human damage recognition complex XPC-HR23B.";
RL   DNA Repair 2:325-336(2003).
RN   [20]
RP   INTERACTION WITH TDG.
RX   PubMed=12505994; DOI=10.1093/emboj/cdg016;
RA   Shimizu Y., Iwai S., Hanaoka F., Sugasawa K.;
RT   "Xeroderma pigmentosum group C protein interacts physically and
RT   functionally with thymine DNA glycosylase.";
RL   EMBO J. 22:164-173(2003).
RN   [21]
RP   UBIQUITINATION, AND INTERACTION WITH DDB2.
RX   PubMed=15882621; DOI=10.1016/j.cell.2005.02.035;
RA   Sugasawa K., Okuda Y., Saijo M., Nishi R., Matsuda N., Chu G.,
RA   Mori T., Iwai S., Tanaka K., Tanaka K., Hanaoka F.;
RT   "UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin
RT   ligase complex.";
RL   Cell 121:387-400(2005).
RN   [22]
RP   INTERACTION WITH CETN2 AND RAD23B, AND MUTAGENESIS OF TRP-848; LEU-851
RP   AND LEU-855.
RX   PubMed=15964821; DOI=10.1128/mcb.25.13.5664-5674.2005;
RA   Nishi R., Okuda Y., Watanabe E., Mori T., Iwai S., Masutani C.,
RA   Sugasawa K., Hanaoka F.;
RT   "Centrin 2 stimulates nucleotide excision repair by interacting with
RT   xeroderma pigmentosum group C protein.";
RL   Mol. Cell. Biol. 25:5664-5674(2005).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94 AND SER-129, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate
RT   cancer cells: identification of phosphoproteins in the LNCaP cell
RT   line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94; THR-169; SER-883;
RP   SER-884 AND SER-891, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94; SER-129; SER-883 AND
RP   SER-884, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94; THR-876; SER-883 AND
RP   SER-884, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-883 AND SER-884, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94; SER-140; SER-397;
RP   SER-398; SER-399; SER-453; SER-460; SER-883; SER-884 AND SER-903, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-81, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [35]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-81, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [36]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-41; LYS-81; LYS-89 AND
RP   LYS-161, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [37]
RP   CHARACTERIZATION OF VARIANT XP-C SER-690.
RX   PubMed=17682058; DOI=10.1128/mcb.02166-06;
RA   Yasuda G., Nishi R., Watanabe E., Mori T., Iwai S., Orioli D.,
RA   Stefanini M., Hanaoka F., Sugasawa K.;
RT   "In vivo destabilization and functional defects of the xeroderma
RT   pigmentosum C protein caused by a pathogenic missense mutation.";
RL   Mol. Cell. Biol. 27:6606-6614(2007).
RN   [38]
RP   CHARACTERIZATION OF VARIANT XP-C SER-690, AND MUTAGENESIS OF PHE-733.
RX   PubMed=17355181; DOI=10.1371/journal.pbio.0050079;
RA   Maillard O., Solyom S., Naegeli H.;
RT   "An aromatic sensor with aversion to damaged strands confers
RT   versatility to DNA repair.";
RL   PLoS Biol. 5:E79-E79(2007).
RN   [39]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18682493; DOI=10.1242/jcs.031708;
RA   Hoogstraten D., Bergink S., Ng J.M., Verbiest V.H., Luijsterburg M.S.,
RA   Geverts B., Raams A., Dinant C., Hoeijmakers J.H., Vermeulen W.,
RA   Houtsmuller A.B.;
RT   "Versatile DNA damage detection by the global genome nucleotide
RT   excision repair protein XPC.";
RL   J. Cell Sci. 121:2850-2859(2008).
RN   [40]
RP   ERRATUM.
RA   Hoogstraten D., Bergink S., Ng J.M., Verbiest V.H., Luijsterburg M.S.,
RA   Geverts B., Raams A., Dinant C., Hoeijmakers J.H., Vermeulen W.,
RA   Houtsmuller A.B.;
RL   J. Cell Sci. 121:2972-2972(2008).
RN   [41]
RP   ERRATUM.
RA   Hoogstraten D., Bergink S., Ng J.M., Verbiest V.H., Luijsterburg M.S.,
RA   Geverts B., Raams A., Dinant C., Hoeijmakers J.H., Vermeulen W.,
RA   Houtsmuller A.B.;
RL   J. Cell Sci. 121:3991-3991(2008).
RN   [42]
RP   FUNCTION, CHARACTERIZATION OF VARIANT OF VARIANT XP-C SER-690, AND
RP   MUTAGENESIS OF TRP-531; TRP-542; PHE-733 AND GLU-755.
RX   PubMed=19609301; DOI=10.1038/emboj.2009.187;
RA   Camenisch U., Trautlein D., Clement F.C., Fei J., Leitenstorfer A.,
RA   Ferrando-May E., Naegeli H.;
RT   "Two-stage dynamic DNA quality check by xeroderma pigmentosum group C
RT   protein.";
RL   EMBO J. 28:2387-2399(2009).
RN   [43]
RP   FUNCTION OF THE XPC COMPLEX.
RX   PubMed=19941824; DOI=10.1016/j.molcel.2009.09.035;
RA   Sugasawa K., Akagi J., Nishi R., Iwai S., Hanaoka F.;
RT   "Two-step recognition of DNA damage for mammalian nucleotide excision
RT   repair: Directional binding of the XPC complex and DNA strand
RT   scanning.";
RL   Mol. Cell 36:642-653(2009).
RN   [44]
RP   FUNCTION, AND MUTAGENESIS OF ASN-754; PHE-756; PHE-797 AND PHE-799.
RX   PubMed=20649465; DOI=10.1089/ars.2010.3399;
RA   Clement F.C., Kaczmarek N., Mathieu N., Tomas M., Leitenstorfer A.,
RA   Ferrando-May E., Naegeli H.;
RT   "Dissection of the xeroderma pigmentosum group C protein function by
RT   site-directed mutagenesis.";
RL   Antioxid. Redox Signal. 14:2479-2490(2011).
RN   [45]
RP   FUNCTION OF THE XPC COMPLEX.
RX   PubMed=20028083; DOI=10.1021/bi901575h;
RA   Neher T.M., Rechkunova N.I., Lavrik O.I., Turchi J.J.;
RT   "Photo-cross-linking of XPC-Rad23B to cisplatin-damaged DNA reveals
RT   contacts with both strands of the DNA duplex and spans the DNA
RT   adduct.";
RL   Biochemistry 49:669-678(2010).
RN   [46]
RP   FUNCTION OF THE XPC COMPLEX, AND INTERACTION WITH TDG AND SMUG1.
RX   PubMed=20798892; DOI=10.4061/2010/805698;
RA   Shimizu Y., Uchimura Y., Dohmae N., Saitoh H., Hanaoka F.,
RA   Sugasawa K.;
RT   "Stimulation of DNA glycosylase activities by XPC Protein Complex:
RT   Roles of protein-protein interactions.";
RL   J. Nucleic Acids 2010:455-459(2010).
RN   [47]
RP   UBIQUITINATION, AND SUMOYLATION.
RX   PubMed=23751493; DOI=10.1083/jcb.201212075;
RA   Poulsen S.L., Hansen R.K., Wagner S.A., van Cuijk L., van Belle G.J.,
RA   Streicher W., Wikstroem M., Choudhary C., Houtsmuller A.B.,
RA   Marteijn J.A., Bekker-Jensen S., Mailand N.;
RT   "RNF111/Arkadia is a SUMO-targeted ubiquitin ligase that facilitates
RT   the DNA damage response.";
RL   J. Cell Biol. 201:797-807(2013).
RN   [48]
RP   FUNCTION, INTERACTION WITH E2F1 AND KAT2A, AND CHARACTERIZATION OF
RP   VARIANT XP-C HIS-334.
RX   PubMed=29973595; DOI=10.1038/s41467-018-05010-0;
RA   Bidon B., Iltis I., Semer M., Nagy Z., Larnicol A., Cribier A.,
RA   Benkirane M., Coin F., Egly J.M., Le May N.;
RT   "XPC is an RNA polymerase II cofactor recruiting ATAC to promoters by
RT   interacting with E2F1.";
RL   Nat. Commun. 9:2610-2610(2018).
RN   [49]
RP   INTERACTION WITH KAT2A.
RX   PubMed=31527837; DOI=10.1038/s41589-019-0354-y;
RA   Semer M., Bidon B., Larnicol A., Caliskan G., Catez P., Egly J.M.,
RA   Coin F., Le May N.;
RT   "DNA repair complex licenses acetylation of H2A.Z.1 by KAT2A during
RT   transcription.";
RL   Nat. Chem. Biol. 15:992-1000(2019).
RN   [50]
RP   STRUCTURE BY NMR OF 847-863 IN COMPLEX WITH CETN2.
RX   PubMed=16533048; DOI=10.1021/bi0524868;
RA   Yang A., Miron S., Mouawad L., Duchambon P., Blouquit Y.,
RA   Craescu C.T.;
RT   "Flexibility and plasticity of human centrin 2 binding to the
RT   xeroderma pigmentosum group C protein (XPC) from nuclear excision
RT   repair.";
RL   Biochemistry 45:3653-3663(2006).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 847-863 IN COMPLEX WITH
RP   CETN2.
RX   PubMed=16627479; DOI=10.1074/jbc.m513667200;
RA   Thompson J.R., Ryan Z.C., Salisbury J.L., Kumar R.;
RT   "The structure of the human centrin 2-xeroderma pigmentosum group C
RT   protein complex.";
RL   J. Biol. Chem. 281:18746-18752(2006).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 847-863 IN COMPLEX WITH
RP   CETN2.
RX   PubMed=17897675; DOI=10.1016/j.jmb.2007.08.046;
RA   Charbonnier J.B., Renaud E., Miron S., Le Du M.H., Blouquit Y.,
RA   Duchambon P., Christova P., Shosheva A., Rose T., Angulo J.F.,
RA   Craescu C.T.;
RT   "Structural, thermodynamic, and cellular characterization of human
RT   centrin 2 interaction with xeroderma pigmentosum group C protein.";
RL   J. Mol. Biol. 373:1032-1046(2007).
RN   [53]
RP   REVIEW ON VARIANTS XP-C.
RX   PubMed=10447254;
RX   DOI=10.1002/(sici)1098-1004(1999)14:1<9::aid-humu2>3.0.co;2-6;
RA   Cleaver J.E., Thompson L.H., Richardson A.S., States J.C.;
RT   "A summary of mutations in the UV-sensitive disorders: xeroderma
RT   pigmentosum, Cockayne syndrome, and trichothiodystrophy.";
RL   Hum. Mutat. 14:9-22(1999).
RN   [54]
RP   VARIANTS XP-C HIS-334 AND VAL-697 INS.
RX   PubMed=8298653; DOI=10.1038/ng1293-413;
RA   Li L., Bales E.S., Peterson C.A., Legerski R.J.;
RT   "Characterization of molecular defects in Xeroderma pigmentosum group
RT   C.";
RL   Nat. Genet. 5:413-417(1993).
RN   [55]
RP   VARIANT XP-C SER-690.
RX   PubMed=10766188;
RA   Chavanne F., Broughton B.C., Pietra D., Nardo T., Browitt A.,
RA   Lehmann A.R., Stefanini M.;
RT   "Mutations in the XPC gene in families with xeroderma pigmentosum and
RT   consequences at the cell, protein, and transcript levels.";
RL   Cancer Res. 60:1974-1982(2000).
CC   -!- FUNCTION: Involved in global genome nucleotide excision repair
CC       (GG-NER) by acting as damage sensing and DNA-binding factor
CC       component of the XPC complex (PubMed:10734143, PubMed:19609301,
CC       PubMed:20649465, PubMed:9734359, PubMed:10873465, PubMed:12509299,
CC       PubMed:12547395, PubMed:19941824, PubMed:20028083,
CC       PubMed:20798892). Has only a low DNA repair activity by itself
CC       which is stimulated by RAD23B and RAD23A. Has a preference to bind
CC       DNA containing a short single-stranded segment but not to damaged
CC       oligonucleotides (PubMed:10734143, PubMed:19609301,
CC       PubMed:20649465). This feature is proposed to be related to a
CC       dynamic sensor function: XPC can rapidly screen duplex DNA for
CC       non-hydrogen-bonded bases by forming a transient nucleoprotein
CC       intermediate complex which matures into a stable recognition
CC       complex through an intrinsic single-stranded DNA-binding activity
CC       (PubMed:10734143, PubMed:19609301, PubMed:20649465). The XPC
CC       complex is proposed to represent the first factor bound at the
CC       sites of DNA damage and together with other core recognition
CC       factors, XPA, RPA and the TFIIH complex, is part of the pre-
CC       incision (or initial recognition) complex (PubMed:9734359,
CC       PubMed:10873465, PubMed:12509299, PubMed:12547395,
CC       PubMed:19941824, PubMed:20028083, PubMed:20798892). The XPC
CC       complex recognizes a wide spectrum of damaged DNA characterized by
CC       distortions of the DNA helix such as single-stranded loops,
CC       mismatched bubbles or single-stranded overhangs (PubMed:9734359,
CC       PubMed:10873465, PubMed:12509299, PubMed:12547395,
CC       PubMed:19941824, PubMed:20028083, PubMed:20798892). The
CC       orientation of XPC complex binding appears to be crucial for
CC       inducing a productive NER (PubMed:9734359, PubMed:10873465,
CC       PubMed:12509299, PubMed:12547395, PubMed:19941824,
CC       PubMed:20028083, PubMed:20798892). XPC complex is proposed to
CC       recognize and to interact with unpaired bases on the undamaged DNA
CC       strand which is followed by recruitment of the TFIIH complex and
CC       subsequent scanning for lesions in the opposite strand in a 5'-to-
CC       3' direction by the NER machinery (PubMed:9734359,
CC       PubMed:10873465, PubMed:12509299, PubMed:12547395,
CC       PubMed:19941824, PubMed:20028083, PubMed:20798892). Cyclobutane
CC       pyrimidine dimers (CPDs) which are formed upon UV-induced DNA
CC       damage esacpe detection by the XPC complex due to a low degree of
CC       structural perurbation. Instead they are detected by the UV-DDB
CC       complex which in turn recruits and cooperates with the XPC complex
CC       in the respective DNA repair (PubMed:9734359, PubMed:10873465,
CC       PubMed:12509299, PubMed:12547395, PubMed:19941824,
CC       PubMed:20028083, PubMed:20798892). In vitro, the XPC:RAD23B dimer
CC       is sufficient to initiate NER; it preferentially binds to
CC       cisplatin and UV-damaged double-stranded DNA and also binds to a
CC       variety of chemically and structurally diverse DNA adducts
CC       (PubMed:20028083). XPC:RAD23B contacts DNA both 5' and 3' of a
CC       cisplatin lesion with a preference for the 5' side. XPC:RAD23B
CC       induces a bend in DNA upon binding. XPC:RAD23B stimulates the
CC       activity of DNA glycosylases TDG and SMUG1 (PubMed:20028083).
CC       {ECO:0000269|PubMed:10734143, ECO:0000269|PubMed:10873465,
CC       ECO:0000269|PubMed:12509299, ECO:0000269|PubMed:12547395,
CC       ECO:0000269|PubMed:19609301, ECO:0000269|PubMed:19941824,
CC       ECO:0000269|PubMed:20028083, ECO:0000269|PubMed:20649465,
CC       ECO:0000269|PubMed:20798892, ECO:0000269|PubMed:9734359}.
CC   -!- FUNCTION: In absence of DNA repair, the XPC complex also acts as a
CC       transcription coactivator: XPC interacts with the DNA-binding
CC       transcription factor E2F1 at a subset of promoters to recruit
CC       KAT2A and histone acetyltransferase complexes (HAT)
CC       (PubMed:29973595, PubMed:31527837). KAT2A recruitment specifically
CC       promotes acetylation of histone variant H2A.Z.1/H2A.Z, but not
CC       H2A.Z.2/H2A.V, thereby promoting expression of target genes
CC       (PubMed:31527837). {ECO:0000269|PubMed:29973595,
CC       ECO:0000269|PubMed:31527837}.
CC   -!- SUBUNIT: Component of the XPC complex composed of XPC, RAD23B and
CC       CETN2 (PubMed:11279143, PubMed:12509233, PubMed:15964821,
CC       PubMed:17897675, PubMed:16627479, PubMed:16533048). Interacts with
CC       RAD23A; the interaction is suggesting the existence of a
CC       functional equivalent variant XPC complex (PubMed:9372924).
CC       Interacts with TDG; the interaction is demonstrated using the
CC       XPC:RAD23B dimer (PubMed:12505994, PubMed:20798892). Interacts
CC       with SMUG1; the interaction is demonstrated using the XPC:RAD23B
CC       dimer (PubMed:20798892). Interacts with DDB2 (PubMed:15882621).
CC       Interacts with CCNH, GTF2H1 and ERCC3 (PubMed:10734143,
CC       PubMed:12509233). Interacts with E2F1 and KAT2A; leading to KAT2A
CC       recruitment to promoters and subsequent acetylation of histones
CC       (PubMed:29973595, PubMed:31527837). {ECO:0000269|PubMed:10734143,
CC       ECO:0000269|PubMed:11279143, ECO:0000269|PubMed:12505994,
CC       ECO:0000269|PubMed:12509233, ECO:0000269|PubMed:15882621,
CC       ECO:0000269|PubMed:15964821, ECO:0000269|PubMed:16533048,
CC       ECO:0000269|PubMed:16627479, ECO:0000269|PubMed:17897675,
CC       ECO:0000269|PubMed:20798892, ECO:0000269|PubMed:29973595,
CC       ECO:0000269|PubMed:31527837, ECO:0000269|PubMed:9372924}.
CC   -!- INTERACTION:
CC       P13288:BGLF4 (xeno); NbExp=9; IntAct=EBI-372610, EBI-1630636;
CC       P41208:CETN2; NbExp=5; IntAct=EBI-372610, EBI-1789926;
CC       Q92466:DDB2; NbExp=4; IntAct=EBI-15950383, EBI-1176171;
CC       P19447:ERCC3; NbExp=2; IntAct=EBI-372610, EBI-1183307;
CC       P32780:GTF2H1; NbExp=3; IntAct=EBI-15950383, EBI-715539;
CC       P62195:PSMC5; NbExp=2; IntAct=EBI-372610, EBI-357745;
CC       P54727:RAD23B; NbExp=6; IntAct=EBI-372610, EBI-954531;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11279143,
CC       ECO:0000269|PubMed:18682493, ECO:0000269|PubMed:8692695}.
CC       Chromosome {ECO:0000269|PubMed:29973595}. Cytoplasm
CC       {ECO:0000269|PubMed:18682493}. Note=Omnipresent in the nucleus and
CC       consistently associates with and dissociates from DNA in the
CC       absence of DNA damage (PubMed:18682493). Continuously shuttles
CC       between the cytoplasm and the nucleus, which is impeded by the
CC       presence of NER lesions (PubMed:18682493).
CC       {ECO:0000269|PubMed:18682493}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q01831-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q01831-2; Sequence=VSP_046344;
CC         Note=No experimental confirmation available.;
CC       Name=3; Synonyms=B;
CC         IsoId=Q01831-3; Sequence=VSP_055890, VSP_055891;
CC   -!- PTM: Ubiquitinated upon UV irradiation; the ubiquitination
CC       requires the UV-DDB complex, appears to be reversible and does not
CC       serve as a signal for degradation (PubMed:15882621,
CC       PubMed:23751493). Ubiquitinated by RNF11 via 'Lys-63'-linked
CC       ubiquitination (PubMed:23751493). Ubiquitination by RNF111 is
CC       polysumoylation-dependent and promotes nucleotide excision repair
CC       (PubMed:23751493). {ECO:0000269|PubMed:15882621,
CC       ECO:0000269|PubMed:23751493}.
CC   -!- PTM: Sumoylated; sumoylation promotes ubiquitination by RNF111.
CC       {ECO:0000269|PubMed:23751493}.
CC   -!- DISEASE: Xeroderma pigmentosum complementation group C (XP-C)
CC       [MIM:278720]: An autosomal recessive pigmentary skin disorder
CC       characterized by solar hypersensitivity of the skin, high
CC       predisposition for developing cancers on areas exposed to sunlight
CC       and, in some cases, neurological abnormalities. The skin develops
CC       marked freckling and other pigmentation abnormalities.
CC       {ECO:0000269|PubMed:10447254, ECO:0000269|PubMed:10766188,
CC       ECO:0000269|PubMed:17355181, ECO:0000269|PubMed:17682058,
CC       ECO:0000269|PubMed:19609301, ECO:0000269|PubMed:29973595,
CC       ECO:0000269|PubMed:8298653}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the XPC family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/XPCID122.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/xpc/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; D21089; BAA04651.1; -; mRNA.
DR   EMBL; AF261901; AAF87574.1; -; Genomic_DNA.
DR   EMBL; AF261892; AAF87574.1; JOINED; Genomic_DNA.
DR   EMBL; AF261893; AAF87574.1; JOINED; Genomic_DNA.
DR   EMBL; AF261894; AAF87574.1; JOINED; Genomic_DNA.
DR   EMBL; AF261895; AAF87574.1; JOINED; Genomic_DNA.
DR   EMBL; AF261896; AAF87574.1; JOINED; Genomic_DNA.
DR   EMBL; AF261897; AAF87574.1; JOINED; Genomic_DNA.
DR   EMBL; AF261898; AAF87574.1; JOINED; Genomic_DNA.
DR   EMBL; AF261899; AAF87574.1; JOINED; Genomic_DNA.
DR   EMBL; AF261900; AAF87574.1; JOINED; Genomic_DNA.
DR   EMBL; KJ535085; AHW56724.1; -; mRNA.
DR   EMBL; AY131066; AAM77801.1; -; Genomic_DNA.
DR   EMBL; AK295711; BAG58555.1; -; mRNA.
DR   EMBL; AC093495; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; FJ695191; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; FJ695192; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC016620; AAH16620.1; -; mRNA.
DR   EMBL; AK222844; BAD96564.1; -; mRNA.
DR   EMBL; X65024; CAA46158.1; -; mRNA.
DR   CCDS; CCDS46763.1; -. [Q01831-1]
DR   PIR; S44345; S44345.
DR   RefSeq; NP_004619.3; NM_004628.4. [Q01831-1]
DR   PDB; 2A4J; NMR; -; B=847-863.
DR   PDB; 2GGM; X-ray; 2.35 A; C/D=847-863.
DR   PDB; 2OBH; X-ray; 1.80 A; C/D=847-863.
DR   PDB; 2RVB; NMR; -; A=109-156.
DR   PDBsum; 2A4J; -.
DR   PDBsum; 2GGM; -.
DR   PDBsum; 2OBH; -.
DR   PDBsum; 2RVB; -.
DR   SMR; Q01831; -.
DR   BioGrid; 113345; 85.
DR   DIP; DIP-31225N; -.
DR   IntAct; Q01831; 64.
DR   MINT; Q01831; -.
DR   STRING; 9606.ENSP00000285021; -.
DR   iPTMnet; Q01831; -.
DR   PhosphoSitePlus; Q01831; -.
DR   SwissPalm; Q01831; -.
DR   BioMuta; XPC; -.
DR   DMDM; 296453081; -.
DR   EPD; Q01831; -.
DR   jPOST; Q01831; -.
DR   MassIVE; Q01831; -.
DR   PaxDb; Q01831; -.
DR   PeptideAtlas; Q01831; -.
DR   PRIDE; Q01831; -.
DR   ProteomicsDB; 19176; -.
DR   ProteomicsDB; 20470; -.
DR   ProteomicsDB; 58003; -. [Q01831-1]
DR   Ensembl; ENST00000285021; ENSP00000285021; ENSG00000154767. [Q01831-1]
DR   Ensembl; ENST00000476581; ENSP00000424548; ENSG00000154767. [Q01831-3]
DR   GeneID; 7508; -.
DR   KEGG; hsa:7508; -.
DR   UCSC; uc062gzd.1; human. [Q01831-1]
DR   CTD; 7508; -.
DR   DisGeNET; 7508; -.
DR   GeneCards; XPC; -.
DR   GeneReviews; XPC; -.
DR   HGNC; HGNC:12816; XPC.
DR   HPA; CAB009932; -.
DR   HPA; HPA035707; -.
DR   HPA; HPA069673; -.
DR   MalaCards; XPC; -.
DR   MIM; 278720; phenotype.
DR   MIM; 613208; gene.
DR   neXtProt; NX_Q01831; -.
DR   OpenTargets; ENSG00000154767; -.
DR   Orphanet; 910; Xeroderma pigmentosum.
DR   PharmGKB; PA37413; -.
DR   eggNOG; KOG2179; Eukaryota.
DR   eggNOG; COG5535; LUCA.
DR   GeneTree; ENSGT00390000005194; -.
DR   HOGENOM; HOG000124671; -.
DR   InParanoid; Q01831; -.
DR   KO; K10838; -.
DR   OMA; EEKWVCV; -.
DR   OrthoDB; 750482at2759; -.
DR   PhylomeDB; Q01831; -.
DR   TreeFam; TF101242; -.
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-HSA-5696394; DNA Damage Recognition in GG-NER.
DR   Reactome; R-HSA-5696395; Formation of Incision Complex in GG-NER.
DR   SIGNOR; Q01831; -.
DR   ChiTaRS; XPC; human.
DR   EvolutionaryTrace; Q01831; -.
DR   GeneWiki; XPC_(gene); -.
DR   GenomeRNAi; 7508; -.
DR   Pharos; Q01831; -.
DR   PRO; PR:Q01831; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000154767; Expressed in 230 organ(s), highest expression level in left lobe of thyroid gland.
DR   ExpressionAtlas; Q01831; baseline and differential.
DR   Genevisible; Q01831; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000109; C:nucleotide-excision repair complex; IDA:UniProtKB.
DR   GO; GO:0000111; C:nucleotide-excision repair factor 2 complex; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0090734; C:site of DNA damage; IEA:Ensembl.
DR   GO; GO:0071942; C:XPC complex; IDA:UniProtKB.
DR   GO; GO:0000405; F:bubble DNA binding; TAS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0000404; F:heteroduplex DNA loop binding; TAS:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0070911; P:global genome nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0031573; P:intra-S DNA damage checkpoint; IEA:Ensembl.
DR   GO; GO:0006298; P:mismatch repair; IBA:GO_Central.
DR   GO; GO:0006289; P:nucleotide-excision repair; IDA:UniProtKB.
DR   GO; GO:0000715; P:nucleotide-excision repair, DNA damage recognition; IDA:UniProtKB.
DR   GO; GO:0000717; P:nucleotide-excision repair, DNA duplex unwinding; TAS:Reactome.
DR   GO; GO:0006294; P:nucleotide-excision repair, preincision complex assembly; TAS:Reactome.
DR   GO; GO:0000720; P:pyrimidine dimer repair by nucleotide-excision repair; IEA:Ensembl.
DR   GO; GO:1901990; P:regulation of mitotic cell cycle phase transition; IMP:UniProtKB.
DR   GO; GO:0010996; P:response to auditory stimulus; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0010224; P:response to UV-B; IEA:Ensembl.
DR   GO; GO:0070914; P:UV-damage excision repair; IDA:CACAO.
DR   GO; GO:1990731; P:UV-damage excision repair, DNA incision; IEA:Ensembl.
DR   DisProt; DP01626; -.
DR   Gene3D; 3.30.70.2460; -; 1.
DR   Gene3D; 3.90.260.10; -; 1.
DR   InterPro; IPR018327; BHD_2.
DR   InterPro; IPR004583; DNA_repair_Rad4.
DR   InterPro; IPR018026; DNA_repair_Rad4_subgr.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR018325; Rad4/PNGase_transGLS-fold.
DR   InterPro; IPR018326; Rad4_beta-hairpin_dom1.
DR   InterPro; IPR018328; Rad4_beta-hairpin_dom3.
DR   InterPro; IPR042488; Rad4_BHD3_sf.
DR   InterPro; IPR036985; Transglutaminase-like_sf.
DR   PANTHER; PTHR12135; PTHR12135; 1.
DR   Pfam; PF10403; BHD_1; 1.
DR   Pfam; PF10404; BHD_2; 1.
DR   Pfam; PF10405; BHD_3; 1.
DR   Pfam; PF03835; Rad4; 1.
DR   SMART; SM01030; BHD_1; 1.
DR   SMART; SM01031; BHD_2; 1.
DR   SMART; SM01032; BHD_3; 1.
DR   SUPFAM; SSF54001; SSF54001; 1.
DR   TIGRFAMs; TIGR00605; rad4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosome; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation; DNA damage;
KW   DNA repair; DNA-binding; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Xeroderma pigmentosum.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:8168482}.
FT   CHAIN         2    940       DNA repair protein complementing XP-C
FT                                cells.
FT                                /FTId=PRO_0000218293.
FT   REGION      496    734       Interaction with RAD23B.
FT   REGION      607    766       Minimal sensor domain involved in damage
FT                                recognition.
FT   REGION      607    741       DNA-binding; preference for heteroduplex
FT                                DNA.
FT   REGION      767    831       DNA-binding; preference for single
FT                                stranded DNA; required for formation of
FT                                stable nucleoprotein complex.
FT   REGION      816    940       Interaction with ERCC2 and GTF2H1.
FT                                {ECO:0000269|PubMed:12509233}.
FT   REGION      847    866       Interaction with CETN2.
FT   MOTIF       390    395       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS     30    177       Glu-rich (acidic).
FT   COMPBIAS     30     34       Poly-Glu.
FT   COMPBIAS    124    130       Poly-Glu.
FT   COMPBIAS    359    395       Lys-rich (basic).
FT   COMPBIAS    408    431       Arg/Lys-rich (basic).
FT   COMPBIAS    432    461       Asp/Glu-rich (acidic).
FT   COMPBIAS    466    493       Arg/Lys-rich (basic).
FT   COMPBIAS    501    507       Poly-Ser.
FT   MOD_RES      94     94       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     129    129       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     140    140       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     169    169       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     397    397       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     398    398       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     399    399       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     453    453       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     460    460       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     876    876       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     883    883       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     884    884       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     891    891       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     903    903       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   CROSSLNK     41     41       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK     81     81       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK     89     89       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    161    161       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ     136    172       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046344.
FT   VAR_SEQ     138    140       ELS -> VKR (in isoform 3).
FT                                {ECO:0000303|PubMed:24722188}.
FT                                /FTId=VSP_055890.
FT   VAR_SEQ     141    940       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:24722188}.
FT                                /FTId=VSP_055891.
FT   VARIANT      16     16       L -> V (in dbSNP:rs1870134).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018894.
FT   VARIANT      48     48       L -> F (in dbSNP:rs2229089).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018895.
FT   VARIANT      86     86       K -> R (in dbSNP:rs3731063).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018896.
FT   VARIANT     287    287       F -> C (in dbSNP:rs35629274).
FT                                /FTId=VAR_057475.
FT   VARIANT     314    314       R -> Q (in dbSNP:rs3731126).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018897.
FT   VARIANT     334    334       P -> H (in XP-C; severe; does not affect
FT                                interaction with KAT2A and transcription
FT                                coactivator activity in absence of DNA
FT                                damage; dbSNP:rs74737358).
FT                                {ECO:0000269|PubMed:29973595,
FT                                ECO:0000269|PubMed:8298653}.
FT                                /FTId=VAR_005846.
FT   VARIANT     492    492       R -> H (in dbSNP:rs2227999).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018898.
FT   VARIANT     499    499       A -> V (in dbSNP:rs2228000).
FT                                {ECO:0000269|PubMed:12177305,
FT                                ECO:0000269|PubMed:8168482,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018899.
FT   VARIANT     511    511       K -> Q (in dbSNP:rs6413541).
FT                                /FTId=VAR_059963.
FT   VARIANT     513    513       M -> I (in dbSNP:rs3731130).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018900.
FT   VARIANT     514    514       C -> S (in dbSNP:rs3731130).
FT                                /FTId=VAR_057476.
FT   VARIANT     632    632       Q -> E (in dbSNP:rs3731139).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018901.
FT   VARIANT     671    671       R -> H (in dbSNP:rs3731140).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018902.
FT   VARIANT     689    689       T -> M (in dbSNP:rs3731152).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018903.
FT   VARIANT     690    690       W -> S (in XP-C; diminishes repair
FT                                activity and impairs DNA binding).
FT                                {ECO:0000269|PubMed:10766188,
FT                                ECO:0000269|PubMed:17355181,
FT                                ECO:0000269|PubMed:17682058,
FT                                ECO:0000269|PubMed:19609301}.
FT                                /FTId=VAR_064039.
FT   VARIANT     697    697       V -> VV (in XP-C; mild).
FT                                {ECO:0000269|PubMed:8298653}.
FT                                /FTId=VAR_005847.
FT   VARIANT     928    928       K -> Q (in dbSNP:rs3731177).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018904.
FT   VARIANT     939    939       Q -> K (in dbSNP:rs2228001).
FT                                {ECO:0000269|PubMed:12177305,
FT                                ECO:0000269|PubMed:8168482,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_005848.
FT   MUTAGEN     531    531       W->A: Slightly diminishes repair activity
FT                                and sligtly impairs DNA binding.
FT                                {ECO:0000269|PubMed:19609301}.
FT   MUTAGEN     542    542       W->A: Slightly diminishes repair activity
FT                                and sligtly impairs DNA binding.
FT                                {ECO:0000269|PubMed:19609301}.
FT   MUTAGEN     733    733       F->A: Diminishes repair activity and
FT                                impairs DNA binding.
FT                                {ECO:0000269|PubMed:17355181,
FT                                ECO:0000269|PubMed:19609301}.
FT   MUTAGEN     754    754       N->A: Reduces DNA repair activity;
FT                                abolishes single-stranded DNA binding;
FT                                reduces binding to homoduplex DNA;
FT                                reduces localization at DNA damaged foci.
FT                                {ECO:0000269|PubMed:20649465}.
FT   MUTAGEN     755    755       E->K: Reduces nuclear mobility and
FT                                impairs repair activity.
FT                                {ECO:0000269|PubMed:19609301}.
FT   MUTAGEN     756    756       F->A: Reduces DNA repair activity;
FT                                abolishes single-stranded DNA binding;
FT                                reduces binding to homoduplex DNA;
FT                                reduces localization at DNA damaged foci.
FT                                {ECO:0000269|PubMed:20649465}.
FT   MUTAGEN     797    797       F->A: Reduces DNA repair activity;
FT                                abolishes single-stranded DNA binding;
FT                                reduces binding to homoduplex DNA;
FT                                reduces localization at DNA damaged foci;
FT                                decreases recruitment of TFIIH complex to
FT                                lesion sites.
FT                                {ECO:0000269|PubMed:20649465}.
FT   MUTAGEN     799    799       F->A: Reduces DNA repair activity;
FT                                abolishes single-stranded DNA binding;
FT                                reduces binding to homoduplex DNA;
FT                                greatly reduces localization at DNA
FT                                damaged foci; decreases recruitment of
FT                                TFIIH complex to lesion sites.
FT                                {ECO:0000269|PubMed:20649465}.
FT   MUTAGEN     848    848       W->A: Reduces NER activity and abolishes
FT                                interaction with CETN2; when associated
FT                                with A-851 and A-855.
FT                                {ECO:0000269|PubMed:15964821}.
FT   MUTAGEN     851    851       L->A: Reduces NER activity and abolishes
FT                                interaction with CETN2; when associated
FT                                with A-848 and A-855.
FT                                {ECO:0000269|PubMed:15964821}.
FT   MUTAGEN     855    855       L->A: Reduces NER activity and abolishes
FT                                interaction with CETN2; when associated
FT                                with A-848 and A-851.
FT                                {ECO:0000269|PubMed:15964821}.
FT   CONFLICT    135    135       E -> Q (in Ref. 5; BAG58555).
FT                                {ECO:0000305}.
FT   CONFLICT    489    489       G -> E (in Ref. 5; BAG58555).
FT                                {ECO:0000305}.
FT   TURN        120    123       {ECO:0000244|PDB:2RVB}.
FT   STRAND      124    126       {ECO:0000244|PDB:2RVB}.
FT   STRAND      134    137       {ECO:0000244|PDB:2RVB}.
FT   HELIX       150    153       {ECO:0000244|PDB:2RVB}.
FT   HELIX       848    861       {ECO:0000244|PDB:2OBH}.
SQ   SEQUENCE   940 AA;  105953 MW;  2F8C80D43FAA1256 CRC64;
     MARKRAAGGE PRGRELRSQK SKAKSKARRE EEEEDAFEDE KPPKKSLLSK VSQGKRKRGC
     SHPGGSADGP AKKKVAKVTV KSENLKVIKD EALSDGDDLR DFPSDLKKAH HLKRGATMNE
     DSNEEEEESE NDWEEVEELS EPVLGDVRES TAFSRSLLPV KPVEIEIETP EQAKTRERSE
     KIKLEFETYL RRAMKRFNKG VHEDTHKVHL LCLLANGFYR NNICSQPDLH AIGLSIIPAR
     FTRVLPRDVD TYYLSNLVKW FIGTFTVNAE LSASEQDNLQ TTLERRFAIY SARDDEELVH
     IFLLILRALQ LLTRLVLSLQ PIPLKSATAK GKKPSKERLT ADPGGSSETS SQVLENHTKP
     KTSKGTKQEE TFAKGTCRPS AKGKRNKGGR KKRSKPSSSE EDEGPGDKQE KATQRRPHGR
     ERRVASRVSY KEESGSDEAG SGSDFELSSG EASDPSDEDS EPGPPKQRKA PAPQRTKAGS
     KSASRTHRGS HRKDPSLPAA SSSSSSSKRG KKMCSDGEKA EKRSIAGIDQ WLEVFCEQEE
     KWVCVDCVHG VVGQPLTCYK YATKPMTYVV GIDSDGWVRD VTQRYDPVWM TVTRKCRVDA
     EWWAETLRPY QSPFMDREKK EDLEFQAKHM DQPLPTAIGL YKNHPLYALK RHLLKYEAIY
     PETAAILGYC RGEAVYSRDC VHTLHSRDTW LKKARVVRLG EVPYKMVKGF SNRARKARLA
     EPQLREENDL GLFGYWQTEE YQPPVAVDGK VPRNEFGNVY LFLPSMMPIG CVQLNLPNLH
     RVARKLDIDC VQAITGFDFH GGYSHPVTDG YIVCEEFKDV LLTAWENEQA VIERKEKEKK
     EKRALGNWKL LAKGLLIRER LKRRYGPKSE AAAPHTDAGG GLSSDEEEGT SSQAEAARIL
     AASWPQNRED EEKQKLKGGP KKTKREKKAA ASHLFPFEQL
//